FDA approves new flu vaccine, but CDC withholds recommendation

The U.S. Food and Drug Administration (FDA) has recently approved a new flu vaccine, mFlusiva, which demonstrated promising results in older adults. The vaccine is developed by Fast Company.

Despite the FDA's approval, the Centers for Disease Control and Prevention (CDC) has not provided a recommendation for the mFlusiva vaccine. This marks a departure from the CDC's established practice where recommendations typically follow FDA approvals.

The situation highlights disruptions in the CDC's vaccine review and recommendation process over the past year. Changes in the administration's vaccine policy and legal challenges have slowed and complicated decision-making, leaving crucial health guidance uncertain.

Medical professionals have voiced concerns that the delays could impede the public's access to the best available protection against vaccine-preventable diseases. While medical societies have begun issuing their own guidance, the absence of official CDC directives creates ambiguity regarding vaccine coverage and usage.